SCHEMBL6882069

SCHEMBL6882069

CCOC(=O)CCSC(=O)OCOC(=O)CC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.40
GAA P10253 2/20 0.39
MGAM O43451 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
TSHR P16473 2/20 0.37
ALDH1A1 P00352 4/20 0.36
TRPA1 O75762 1/20 0.36
KDM4E B2RXH2 3/20 0.36
TDP1 Q9NUW8 1/20 0.36
SOAT1 P35610 1/20 0.34
CYP4F2 P78329 2/20 0.34
CYP4A11 Q02928 2/20 0.34
MAPT P10636 3/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
HPGD P15428 2/20 0.34
POLB P06746 2/20 0.34
LMNA P02545 2/20 0.33
KMT2A Q03164 1/20 0.33
NR1I2 O75469 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20836682 0.87 CYP1A2 (0.47) CYP1A2GAAMGAMSIMGAM2
SCHEMBL6886661 0.85 CYP1A2 (0.37) CYP1A2GAAMGAMSIMGAM2
SCHEMBL6885640 0.83 CYP1A2 (0.36) CYP1A2GAAMGAMSIMGAM2
SCHEMBL6887048 0.81 LMNA (0.42) TSHRMAPTLMNA
SCHEMBL18655543 0.78 CYP1A2 (0.34) CYP1A2TSHRALDH1A1TDP1MAPT
SCHEMBL13402824 0.77 CYP1A2 (0.50) CYP1A2GAAMGAMSIMGAM2
SCHEMBL6887486 0.77 MAPT (0.39) TSHRALDH1A1KDM4ETDP1MAPT
SCHEMBL1507260 0.77 NAAA (0.39) CYP1A2GAAMGAMSIMGAM2
SCHEMBL18113054 0.76 CYP1A2 (0.53) CYP1A2GAAMGAMSIMGAM2
SCHEMBL18113242 0.76 TSHR (0.46) CYP1A2GAAMGAMSIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040254182-A1 Enhanced propertied pharmaceuticals ROHM AND HAAS COMPANY 2004-12-16 US disclosed
EP-1272463-A1 ENHANCED PROPERTIED PHARMACEUTICALS ROHM AND HAAS COMPANY (US) 2003-01-08 EP disclosed
WO-2002072559-A1 PROCESS TO INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS ROHM AND HAAS COMPANY (US) 2002-09-19 WO disclosed
US-20010039343-A1 Process to intermediates for biologically active compounds MULVIHILL MARK JOSEPH (US) 2001-11-08 US disclosed
WO-2001056358-A2 ENHANCED PROPERTIED PESTICIDES ROHM AND HAAS COMPANY (US) 2001-08-09 WO disclosed
WO-2001054481-A2 ENHANCED PROPERTIED PHARMACEUTICALS ROHM AND HAAS COMPANY (US) 2001-08-02 WO disclosed
WO-2001055082-A2 INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS ROHM AND HAAS COMPANY (US) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254182-A1 Enhanced propertied pharmaceuticals ABCB1, ABCB11, ABCG2 CYP1A2 85/4885GAA 689/4885MGAM 3909/4885
US-20010039343-A1 Process to intermediates for biologically active compounds DDT, CYP4X1, CYP1B1 CYP1A2 16/4885GAA 265/4885MGAM 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.